Semaglutide biosimilar (Zhuhai United)

司美格鲁肽生物类似药（珠海联邦）

Report date: 2026/04/01 11:19:28

Base Information

Drug NameSemaglutide biosimilar (Zhuhai United)
Drug Alias Name司美格鲁肽索玛鲁肽生物类似药（珠海联邦）
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsOverweightObesityDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesZhuhai United Laboratories Co LtdZhongshan Branch of Zhuhai United Laboratories Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesZhuhai Federation Biomedicine Co LtdLianbang Biotechnology (Zhuhai Hengqin) Co LtdZhongshan Branch of Zhuhai United Laboratories Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsOverweightObesityDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A